

Hertz Daniel (Orcid ID: 0000-0003-0501-1035)

1

Muscle Mass Affects Paclitaxel Systemic Exposure and May Inform Personalized Paclitaxel Dosing

¹Daniel L. Hertz, PharmD, PhD, dlhertz@med.umich.edu

¹Li Chen, chenliw@med.umich.edu

²N. Lynn Henry, MD, PhD, norahh@med.umich.edu

²Jennifer J Griggs, MD, MPH jengrigg@med.umich.edu

²Daniel F Hayes, MD, hayesdf@med.umich.edu

³Brian A. Derstine, MS, bderstin@med.umich.edu

³Grace L. Su, MD, gsu@med.umich.edu

³Stewart C Wang, MD, PhD, stewartw@med.umich.edu

¹Manjunath P. Pai, PharmD, amitpai@med.umich.edu

Corresponding Author:

Daniel L Hertz

428 Church St.

Room 3054 College of Pharmacy

Ann Arbor, MI 48109-1065

Office phone: (734) 763-0015

Fax: (734) 763-4480

E-mail: DLHertz@med.umich.edu

Affiliations:

¹Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI, United States, 48109-1065

²Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan Medical School, Ann Arbor, MI

³Morphomic Analysis Group, University of Michigan Medical School, Ann Arbor, MI

Running Title: Muscle mass and paclitaxel exposure

Keywords: paclitaxel, pharmacokinetics, peripheral neuropathy, therapeutic drug monitoring, muscle mass, sarcopenia, modeling and simulation, sarcopenia, morphomics

Conflict of Interest: DLH has an informal, unpaid collaborative relationship with Saladax Inc., a company that offers CLIA-approved paclitaxel measurement. Saladax was not involved in the design, conduct, analysis, or sponsorship of this trial, and had no contribution to the writing of this manuscript. SCW owns equity in Prenovo, Applied Morphomics, Inc and EIQ, none of which were involved in this research.

Funding: This research was funded in part by the National Center for Advancing Translation Sciences (NCATS National Cancer 2UL1TR000433, KL2TR000434) (DLH) and National Cancer Institute (NCI

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: [10.1111/bcp.15244](https://doi.org/10.1111/bcp.15244)

P30CA046592) through use of the UM Pharmacokinetics Core. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH, NCATS or NCI.

Ethics and Integrity: Data will be made available upon reasonable request to the corresponding author. The initial prospective clinical study was approved by the University of Michigan IRBMed (HUM00086259) and registered at clinicaltrials.gov (NCT02338115). All participants signed written informed consent.

Author Contribution: DLH: Designed and oversaw clinical study, designed and oversaw analysis, wrote manuscript; LC: Collected radiologic and clinical data, assisted pharmacokinetic analysis, reviewed manuscript; NLH, JJG, DFH: Enrolled participants, reviewed manuscript; BAD, GLS, SCW: Analyzed radiologic data, estimated body composition, reviewed manuscript; MPP: Conducted pharmacokinetic analysis, reviewed manuscript;

What is Already Known About this Subject

1. Patients with low muscle mass (i.e., sarcopenia) have increased risk of toxicity from chemotherapy, including paclitaxel-induced peripheral neuropathy.
2. Paclitaxel-induced peripheral neuropathy is primarily dependent on systemic paclitaxel exposure.
3. Low muscle mass increases systemic exposure of some chemotherapeutic agents, but its effect on paclitaxel is not established.

What this Study Adds

1. Low muscle mass increases paclitaxel maximum concentration by decreasing volume of distribution.
2. This likely explains the higher incidence of paclitaxel toxicity.
3. Extending the paclitaxel infusion in patients with low muscle mass is expected to normalize their maximum concentration and may reduce peripheral neuropathy.

Abstract

Aim: Patients with low muscle mass have increased risk of paclitaxel-induced peripheral neuropathy, which is dependent on systemic paclitaxel exposure. Dose optimization may be feasible through the secondary use of radiologic data for body composition. The objective of this study was to interrogate morphomic parameters as predictors of paclitaxel pharmacokinetics to identify alternative dosing strategies that may improve treatment outcomes.

Methods: This was a secondary analysis of female patients with breast cancer scheduled to receive 80 mg/m² weekly paclitaxel infusions. Paclitaxel was measured at the end of initial infusion to estimate maximum concentration (C_{max}). Computed tomography (CT) scans were used to measure 29 body composition features for inclusion in pharmacokinetic modeling. Monte Carlo simulations were performed to identify infusion durations that limit the probability of exceeding $C_{max} > 2,885$ ng/mL, which was selected based on prior work linking this to an unacceptable risk of peripheral neuropathy.

Results: Thirty-nine patients were included in the analysis. The optimal model was a 2-compartment pharmacokinetic model with T11 skeletal muscle area as a covariate of paclitaxel volume of distribution (Vd). Simulations suggest that extending infusion of the standard paclitaxel dose from 1-hour to 2- and 3-hours in patients who have skeletal muscle area 4,907-7,080 mm² and <4,907 mm², respectively, would limit risk of $C_{max} > 2,885$ ng/mL to <50%, consequently reducing neuropathy, while marginally increasing overall systemic paclitaxel exposure.

Conclusion: Extending paclitaxel infusion duration in ~25% of patients who have low skeletal muscle area is predicted to reduce peripheral neuropathy while maintaining systemic exposure, suggesting that personalizing paclitaxel dosing based on body composition may improve treatment outcomes.

Introduction

Paclitaxel is a chemotherapeutic agent commonly used for treatment of several solid tumor types including breast, lung, and ovarian cancer. Like most chemotherapy agents, paclitaxel is dosed based on body surface area (BSA)(1), including the 1-hour 80 mg/m² weekly or 3-hour 175 mg/m² every two or three week standard regimens for breast cancer(2,3). These “maximum tolerated doses” are believed to maximize efficacy while maintaining an acceptable risk of severe toxicity. In the case of weekly paclitaxel, the dose limiting toxicity is peripheral neuropathy (PN), which is characterized by numbness, tingling, pain and/or loss of function in the hands and feet(4). During a pivotal phase III clinical trial of weekly paclitaxel for breast cancer, the protocol doses were revised from 100 mg/m² to 80 mg/m² weekly due to a determination that the 30% incidence of severe (grade 3+) PN was unacceptable but 24% incidence was acceptable(3). The ~25% incidence of severe PN from weekly 1-hour infusions of 80 mg/m², which is the standard weekly dose used in clinical practice, can be inferred to be the maximally acceptable rate of severe or treatment limiting toxicity(5,6).

There has been substantial effort to identify predictors of chemotherapy-induced PN(7) that could inform personalized treatment(8). Perhaps the most well-validated predictor of paclitaxel-induced PN is systemic paclitaxel concentrations, or pharmacokinetics (PK) (See Table 1 in (9)). Several studies of patients receiving weekly paclitaxel have found that higher maximum concentration at the end of infusion (C_{max}) or longer duration of systemic concentration remaining above 0.05 uM (equivalent to 42.7 ng/mL, $T_{C>0.05}$) are associated with increased PN risk(10-12). One analysis of patients receiving weekly paclitaxel (n=141) found that patients with grade 3 PN had significantly higher C_{max} (4,370 ng/mL)

and $T_{c>0.05}$ (15.2 hours) compared with patients who had grades 0/1 PN (C_{max} : 1,394-2,896 ng/mL, $T_{c>0.05}$: 7.6-12.9 hours)(11). Simulations in the UMCC2014.002 cohort (n=60) determined the optimal systemic paclitaxel exposures that are associated with maximally acceptable (~25%) risk of treatment-limiting PN in patients receiving weekly paclitaxel are C_{max} = 2,885 ng/mL and $T_{c>0.05}$ = 14.06 hours (10). Every standard deviation increase in C_{max} or $T_{c>0.05}$ increased the risk of treatment-limiting PN by 174% and 79%, respectively. Randomized controlled trials in patients with lung cancer receiving every 3-week paclitaxel demonstrate that personalized paclitaxel dosing to achieve a target $T_{c>0.05}$ reduces PN and overall toxicity without reducing efficacy (13,14).

Another biomarker that has been repeatedly found to increase chemotherapy toxicity risk is low muscle mass, or sarcopenia (reviewed in (15)). Sarcopenic patients have higher incidence of toxicity from paclitaxel(16) as well as higher PN risk from oxaliplatin (17), another neurotoxic chemotherapy agent. Although muscle mass has been reported to affect PK of some chemotherapeutic drugs(15,18-21), a recent study did not detect an effect on paclitaxel PK(22). If sarcopenia affects paclitaxel PK and consequently increases PN risk, it may be possible to personalize dosing based on muscle mass to reduce PN and improve paclitaxel treatment outcomes.

Patients with breast cancer often undergo radiologic assessments such as computed tomography (CT) and magnetic resonance imaging (MRI) to assess disease stage or monitor disease progression. Innovative methods have been developed to translate existing CT data into body composition metrics, a discipline known as morphomics(23,24). Quantitative body composition data derived from existing CT data may deliver a useful stratification tool that can improve paclitaxel safety

through personalized dosing. The objective of this study was to perform PK modeling and simulation in the UMCC2014.002 cohort to compare the current BSA dosing standard to new morphomic metrics PK and propose personalized weekly paclitaxel dosing strategies that could reduce PN without compromising efficacy.

Methods:**Patients and Pharmacokinetic Data:**

This was a secondary PK analysis of participants who were previously described in detail (10). Briefly, adult female patients scheduled to receive 1-hour infusions of 80 mg/m² paclitaxel weekly for 12 weeks for curative breast cancer treatment at the University of Michigan Rogel Cancer Center were enrolled on an observational clinical trial (NCT02338115) before their first paclitaxel dose. This study was approved by the University of Michigan IRBMed (HUM00086259) and was conducted in accordance with the Declaration of Helsinki including obtaining written informed consent from all participants. DLH was the principal investigator and NLH was the primary clinical investigator of the observational trial. Paclitaxel dosing was administered according to the Rogel Cancer Center's standard protocol including use of actual body weight to calculate BSA, administration of standard pre-treatment medications, and infusing the first dose over 90 minutes to monitor for infusion reactions.

Sample collection and paclitaxel concentration measurement were previously described in detail(10). Briefly, blood samples were collected within the last 10 minutes of the first paclitaxel infusion to estimate the maximum concentration (C_{max}) and 16-26 hours after the start of the first paclitaxel infusion to estimate the amount of time the patient's systemic concentration remained above 0.05 uM (or 42.7 ng/mL, $T_{c>0.05}$)(25). All samples were immediately placed on ice and processed within 10 minutes of collection to isolate plasma. Paclitaxel plasma concentration was measured by the University of Michigan College of Pharmacy Pharmacokinetics Core using a liquid chromatography/mass spectroscopy assay that enables quantitation of paclitaxel concentrations over the linear range of 5–5,000 ng/mL (Additional details of paclitaxel assay performance in **Supplementary Methods**) (10).

Imaging Data Cleaning:

The University of Michigan electronic medical record (MiChart) was queried for all computed tomography (CT) scans for all observational study participants. Only CT scans that occurred within 12 months of the date of first paclitaxel infusion were included in the analysis. CT scans were processed using analytic morphomics to estimate 29 unique parameters (**Supplemental Table 1**) at each of the seven vertebral levels (e.g., Lumbar 1-4, Thoracic 10-12), as previously described(23,24).

Paclitaxel Pharmacokinetic Modeling:

Population PK analysis was performed using Monolix Version 2020R1 (Antony, France: Lixoft SAS, 2020). Briefly, a 1- and 2- compartment model with zero-order input, elimination, and transfer-rate constants were tested to select the base structural model. The presence of a large number of potential covariates (~200 morphomic parameters) and clinical covariates (age, race, body surface area (BSA), albumin) required use of the automated covariate building algorithms in Monolix (26). We tested both the Conditional Sampling use for Stepwise Approach based on Correlations (COSSAC) test as well as the classic stepwise covariate modeling (SCM) method at one vertebral level to identify the principal covariates (**Supplemental Figure 1**). Although more time intensive, the SCM method was selected for all other vertebral levels based on the model fits. Next, we identified the vertebral level that best fit the data with a covariate structured model. For fair comparison of likelihood results, we limited the study sample to participants with the same amount of information at each vertebral level. A manual stepwise covariate model approach was used to create the most parsimonious model to aid future clinical implementation. We evaluated both a rate constant (V, k, k12, K21) and clearance parameterized (CL, V1, Q, V2) structural model. The final model structure was then used to fit all available data at that

vertebral level to generate the base (no-covariate), BSA-structured, and morphomics-structured model. We also tested additive, proportional, and combined residual error models. Model discrimination was based on the Akaike Information Criterion (AIC), with diagnostic evaluation of the non-parametric distributional error (NPDE), individual weighted residuals, and other goodness of fit plots.

Simulations of Infusion Duration to Prevent Peripheral Neuropathy:

The final population PK model was evoked in Simulx Version2020R1 (Antony, France: Lixoft SAS, 2020) and used to simulate the concentration-time profile of paclitaxel 80 mg/m² infused over 1, 2 and 3 hours. The simulations (n=1000 virtual subjects) were based on the principal covariate predictive of the PK and performed at stepwise values across the expected distribution of this covariate in the population. The probability of achieving a $C_{max} \geq 2,885$ ng/mL or $T_{c>0.05} \geq 14.06$ hours was computed for each dose and covariate simulation, as our prior work in this cohort indicates that $C_{max} = 2,885$ ng/mL and $T_{c>0.05} = 14.06$ hours are the exposures associated with maximally acceptable (25%) risk of treatment-limiting PN(10). A scatter plot of the probability of achieving the aforementioned pharmacodynamic targets over the SMA were generated and fit using non-linear regression in Stata SE version 17 (StataCorp LLC, College Station, Texas, USA). A logistic function (symmetric sigmoid shape) with no constant [Probability of Target attainment = $\beta_1/(1 + exp(-\beta_2 \times (SMA - \beta_3)))$] best fit these relationships and was used to identify cut-points at the 50% probability of pharmacodynamic target attainment for the C_{max} or $T_{c>0.05}$ parameter.

Results:**Patients, Pharmacokinetic, and Morphomic Data:**

Of the 60 patients included in the observational clinical study, 57 had paclitaxel measurements available at both time points. Of these 57 patients, CT scans within one year were available for 39 patients, all of which generated morphomics measurements at Thoracic 11 (T11). (**Figure 1**). Similar to the overall cohort, participants were mostly White (90%) with a mean age of 50 and BSA of 1.8 m² (**Table 1**).

Paclitaxel Pharmacokinetic Modeling:

The models identified by SCM at each vertebral level included various combinations of one clinical (albumin) and 9 morphomics covariates (**Supplemental Table 2**, **Supplemental Figure 2**). The best model at any vertebral level included three morphomics measurements: skeletal muscle area (SMA) and visceral fat area (VFA) as covariates on volume of distribution (Vd) and vertebra slab height (VSH) as a covariate on elimination rate constant (k), from T11 and no clinical covariates. Further model exploration at T11 indicates that there is minimal benefit from including all 10 or three covariates, compared with a more parsimonious model with a single covariate (**Supplemental Tables 3 and 4**).

Models with SMA had lower AIC values compared to models that did not include this parameter. The CL structured model had lower AIC values than the k structured models. In comparison with the base (no covariates) and BSA-structured model, the morphomic model including SMA has a lower AIC with clear improvement in the relative standard error of the random effect terms (**Table 2 and Supplemental Table 5**). This final morphomic model with only SMA as a covariate of volume of distribution (central and peripheral) has a >2 point (6.4 point) difference in AIC compared to the BSA-structured model that is

regarded as a substantive difference(27). Model diagnostics and performance are provided in

Supplemental Figures 3-6.

Identification of Optimal Infusion Duration to Prevent Peripheral Neuropathy:

The final PK model was used in simulations to identify optimal infusion durations for patients with varying SMA (4,000-12,000 mm² in increments of 1,000 mm²). Since the main effect of SMA was on Vd, not elimination rate (k), simulations focused on the threshold of C_{max} ≥ 2,885 ng/mL. The simulation was conducted to identify ranges of SMA for which infusion durations should be increased from 1-hour to 2- and 3-hours to retain <50% chance of C_{max} ≥ 2,885 ng/mL. Based on this threshold, patients with SMA >7,080 mm² should receive the standard 1-hour paclitaxel infusion, those with SMA 4,907-7,080 mm² should receive a 2-hour infusion and those with SMA <4,907 mm² should receive a 3-hour infusion (**Figure 2**). These thresholds correspond to approximately 2% (skeletal muscle area <4,907 mm²) and 15% (4,907-7,080 mm²) of 50-year-old (median in our cohort) female patients(23). Extending the infusion duration marginally increases overall exposure and T_{c>0.05}; less than 25% of patients receiving these recommended infusion durations exceed the threshold T_{c>0.05}> 14.06 (**Supplemental Figure 7**).

Discussion

Patients with sarcopenia have increased toxicity risk from many chemotherapy drugs(15-17,28-31). including paclitaxel(16). Paclitaxel-induced PN is primarily determined by systemic paclitaxel exposure, including maximum concentration (10,11). Although sarcopenia affects PK of some chemotherapy agents(15,18-21), an effect on paclitaxel PK has not previously been detected (22). The results of this secondary PK analysis of a prospectively enrolled cohort of patients receiving paclitaxel indicate that lower muscle mass increases maximum paclitaxel concentration, with minimal effect on overall exposure, and that extending paclitaxel infusions to 2 or 3 hours in patients with low muscle mass may reduce PN while maintaining treatment efficacy.

A retrospective analysis of 40 patients receiving taxanes for metastatic breast cancer found that the sarcopenic patients (n=23) experienced greater incidence of grade 3-4 toxicity (57% vs. 18%, p=0.02) and hospitalization (39% vs. 0%, p=0.005)(16). Additionally, analyses of two cohorts of patients with metastatic colorectal cancer receiving combination chemotherapy containing neurotoxic oxaliplatin demonstrate that sarcopenia increases risk of chemotherapy-induced PN(17). Although these are mostly small retrospective studies with varying definitions of body composition and toxicity, the consistent finding that sarcopenia increases toxicity risk strongly suggests this is a real phenomenon. Among several potential mechanistic explanations, perhaps the most likely is that body composition affects systemic chemotherapy exposure, which has been demonstrated for several chemotherapeutic agents(15,18-21). However, a recent analysis in 184 patients with esophageal cancer found that skeletal muscle or adipose tissue measures were not superior to BSA in explaining paclitaxel PK, specifically the paclitaxel metabolic elimination rate (VM_{EL})(22). This is consistent with our results indicating that muscle

mass affects paclitaxel volume of distribution, and consequently maximum concentration, but not clearance. Systematic reviews of the effect of body composition, specifically the weight-loss condition cachexia, reveal unpredictable effects on drug PK with various putative mechanisms(32). The effect of sarcopenia on increasing maximum concentration may be a direct effect on paclitaxel distribution or a secondary effect on changes in protein binding, as paclitaxel is highly bound to albumin and alpha 1-acid glycoprotein(33). Albumin was one of 10 initially identified covariates in this analysis (Supplemental Table 2) but it was not retained in later models, and further analyses to understand the complex interplay between albumin, morphomics, and paclitaxel PK are not possible in this modestly sized cohort.

ASCO guidelines recommend that actual body weight be used when calculating doses for BSA-based dosing in obese patients(1). However, there is evidence that patients with higher body mass index receive less benefit from BSA-based taxane dosing(34) indicating that taxane dose optimization could improve treatment outcomes. Several strategies for personalized paclitaxel treatment have been suggested(8). The most intensively pursued strategy is therapeutic drug monitoring (TDM), in which systemic paclitaxel concentrations are measured during treatment to inform personalized dose adjustments to achieve target systemic exposure. Two prospective randomized clinical trials have demonstrated that paclitaxel TDM reduces toxicity without reducing efficacy(13,14). However, there has been minimal clinical uptake of paclitaxel TDM, which may be due to the general lack of familiarity or acceptance of TDM in oncology(35). Another possible explanation is a concern, both from medical oncologists and patients(36), that reducing paclitaxel doses could reduce treatment efficacy. Our simulations suggest an approach that would not require drug concentration measurement or dose

reduction, but would instead recommend that about 1 out of 6 patients with early stage breast cancer with lower muscle mass receive an extended 2- or 3-hour infusion of 80 mg/m² instead of the standard 1-hour infusion. This approach would maintain full paclitaxel dosing and, based on our simulation, minimally increase overall time above a threshold concentration ($T_{c>0.05}$), which should, if anything, slightly enhance treatment efficacy. The inconvenience and cost of extended infusion time would likely be worth the avoidance of PN and its long-term effects on quality of life(37,38). PN reduction would also avoid paclitaxel treatment disruption(5,39), potentially enhancing the number of full doses that can be administered and efficacy(30,40). Prospective studies are being developed to demonstrate that muscle mass-based dosing reduces supra-therapeutic exposure and PN, while maintaining or perhaps improving treatment efficacy.

This study demonstrates an effect of low muscle mass on paclitaxel systemic exposure. This analysis was conducted in a cohort of prospectively accrued patients with systematically collected PK data. We integrated contemporary body composition analysis within PK modeling to identify the association, followed by simulation to propose personalized infusion durations that could reduce toxicity while maintaining full dosing and treatment efficacy. However, this analysis had several limitations that are worth considering. First, this study was conducted in a modestly sized cohort (n=39) with only two paclitaxel concentration measurements during the first paclitaxel infusion and used available CT scans. Larger retrospective studies could be useful to confirm the effect of sarcopenia on maximum systemic concentration prior to prospective interventional studies of personalized dosing. Using CT scans up to 12 months prior to treatment may have also introduced some variability as they may not accurately represent the patient's body composition at the time of treatment. Additionally, the PK thresholds used

in this study have not been validated. Regardless of whether these are the optimal PK thresholds, our results strongly indicate a biologically plausible effect of muscle mass on paclitaxel C_{max} and provide thresholds for prospective studies that attempt to normalize PK and toxicity risk in sarcopenic patients. We acknowledge the possibility that C_{max} is not causally related to PN and that these prospective trials will fail to demonstrate a clinical benefit to extended infusion duration. Clinical use of this strategy would require CT scans prior to dosing, which may limit this approach to only patients receiving treatment in the metastatic or high-risk adjuvant setting. Low risk patients who do not have an available CT scan would require a CT scan, with or without contrast(41), or muscle area measurement via another modality including MRI, bio-electrical impedance analysis, or panoramic ultrasound.

In conclusion, this secondary PK analysis demonstrates that sarcopenia increases maximum systemic paclitaxel concentration, which likely explains the increased PN risk in paclitaxel treated patients. Simulations indicate that extending infusion by 1-2 hours in the ~17% of patients with the lowest muscle mass may reduce supra-therapeutic exposure and PN. Prospective studies are needed to demonstrate that this approach improves paclitaxel treatment outcomes prior to translation into clinical practice.

Figure Legends

Figure 1: Patient Flow Diagram Describing Patient Matriculation from Initial Observational Study into this Analysis. Of the 60 patients in the observational study, 39 were evaluable in this analysis based on

complete paclitaxel pharmacokinetic data and CT scans available to generate morphomics measures at T11.

Figure 2: Infusion Duration to Prevent Supratherapeutic Paclitaxel Dosing. The relationship between skeletal muscle area (mm^2 , x-axis) and risk of supratherapeutic exposure ($C_{\max} \geq 2,885$) is plotted for a 1-hour (solid line), 2-hour (hatched line), and 3-hour (dotted line) infusion of paclitaxel 80 mg/m^2 . Patients with skeletal muscle area $<7,080$ and $<4,907 \text{ mm}^2$ should receive a 2-hour and 3-hour infusion, respectively, to reduce their risk of supratherapeutic exposure and peripheral neuropathy.

References:

1. Griggs JJ, Bohlke K, Balaban EP, Dignam JJ, Hall ET, Harvey RD, et al. Appropriate Systemic Therapy Dosing for Obese Adult Patients With Cancer: ASCO Guideline Update. *J Clin Oncol* 2021;39(18):2037-48. doi: 10.1200/JCO.21.00471. Epub 2021 May 3.
2. Budd GT, Barlow WE, Moore HC, Hobday TJ, Stewart JA, Isaacs C, et al. SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. *J Clin Oncol* 2015;33(1):58-64 doi 10.1200/jco.2014.56.3296.
3. Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, et al. Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840. *Journal of Clinical Oncology* 2008;26(10):1642-9 doi 10.1200/JCO.2007.11.6699.
4. Rowinsky EK, Chaudhry V, Cornblath DR, Donehower RC. Neurotoxicity of Taxol. *Journal of the National Cancer Institute Monographs* 1993;(15)(15):107-15.
5. Loprinzi CL, Lacchetti C, Bleeker J, Cavaletti G, Chauhan C, Hertz DL, et al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. *J Clin Oncol* 2020;14(10):01399.
6. Speck RM, Sammel MD, Farrar JT, Hennessy S, Mao JJ, Stineman MG, et al. Impact of chemotherapy-induced peripheral neuropathy on treatment delivery in nonmetastatic breast cancer. *J Oncol Pract* 2013;9(5):e234-40 doi 10.1200/jop.2012.000863.
7. Chan A, Hertz DL, Morales M, Adams EJ, Gordon S, Tan CJ, et al. Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN): MASCC neurological complications working group overview. *Support Care Cancer* 2019;27(10):3729-37 doi 10.1007/s00520-019-04987-8.
8. Krens SD, McLeod HL, Hertz DL. Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy. *Pharmacogenomics* 2013;14(5):555-74 doi 10.2217/pgs.13.33 [doi].
9. Hertz DL. Exploring pharmacogenetics of paclitaxel- and docetaxel-induced peripheral neuropathy by evaluating the direct pharmacogenetic-pharmacokinetic and pharmacokinetic-neuropathy relationships. *Expert Opin Drug Metab Toxicol* 2021;6:1-13.
10. Hertz DL, Kidwell KM, Vangipuram K, Li F, Pai MP, Burness M, et al. Paclitaxel Plasma Concentration After the First Infusion Predicts Treatment-Limiting Peripheral Neuropathy. *Clin Cancer Res* 2018 doi 10.1158/1078-0432.ccr-18-0656.
11. de Graan A-JM, Elens L, Sprowl JA, Sparreboom A, Friberg LE, van der Holt B, et al. CYP3A4*22 Genotype and Systemic Exposure Affect Paclitaxel-Induced Neurotoxicity. *Clinical Cancer Research* 2013;19(12):3316-24 doi 10.1158/1078-0432.CCR-12-3786.
12. Mielke S, Sparreboom A, Steinberg SM, Gelderblom H, Unger C, Behringer D, et al. Association of Paclitaxel Pharmacokinetics with the Development of Peripheral Neuropathy in Patients with Advanced Cancer. *Clinical Cancer Research* 2005;11(13):4843-50 doi 10.1158/1078-0432.CCR-05-0298.

13. Joerger M, von Pawel J, Kraff S, Fischer JR, Eberhardt W, Gauler TC, et al. Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC). *Ann Oncol* 2016;27(10):1895-902 doi 10.1093/annonc/mdw290.
14. Zhang J, Zhou F, Qi H, Ni H, Hu Q, Zhou C, et al. Randomized study of individualized pharmacokinetically-guided dosing of paclitaxel compared with body-surface area dosing in Chinese patients with advanced non-small cell lung cancer. *Br J Clin Pharmacol* 2019 doi 10.1111/bcp.13982.
15. Hopkins JJ, Sawyer MB. A review of body composition and pharmacokinetics in oncology. *Expert Rev Clin Pharmacol* 2017;10(9):947-56. doi: 10.1080/17512433.2017.1347503. Epub 2017 Jul 5.
16. Shachar SS, Deal AM, Weinberg M, Nyrop KA, Williams GR, Nishijima TF, et al. Skeletal Muscle Measures as Predictors of Toxicity, Hospitalization, and Survival in Patients with Metastatic Breast Cancer Receiving Taxane-Based Chemotherapy. *Clin Cancer Res* 2017;23(3):658-65. doi: 10.1158/078-0432.CCR-16-940. Epub 2016 Aug 3.
17. Ali R, Baracos VE, Sawyer MB, Bianchi L, Roberts S, Assenat E, et al. Lean body mass as an independent determinant of dose-limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens. *Cancer Med* 2016;5(4):607-16. doi: 10.1002/cam4.621. Epub 2016 Jan 27.
18. Prado CM, Lima IS, Baracos VE, Bies RR, McCargar LJ, Reiman T, et al. An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity. *Cancer Chemother Pharmacol* 2011;67(1):93-101. doi: 10.1007/s00280-010-1288-y. Epub 2010 Mar 5.
19. Mir O, Coriat R, Blanchet B, Durand JP, Boudou-Rouquette P, Michels J, et al. Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. *PLoS One* 2012;7(5):e37563. doi: 10.1371/journal.pone.0037563. Epub 2012 May 30.
20. Massicotte MH, Borget I, Broutin S, Baracos VE, Leboulleux S, Baudin E, et al. Body composition variation and impact of low skeletal muscle mass in patients with advanced medullary thyroid carcinoma treated with vandetanib: results from a placebo-controlled study. *J Clin Endocrinol Metab* 2013;98(6):2401-8. doi: 10.1210/jc.2013-1115. Epub 2013 Mar 29.
21. Wong AL, Seng KY, Ong EM, Wang LZ, Oscar H, Cordero MT, et al. Body fat composition impacts the hematologic toxicities and pharmacokinetics of doxorubicin in Asian breast cancer patients. *Breast Cancer Res Treat* 2014;144(1):143-52. doi: 10.1007/s10549-014-2843-8. Epub 2014 Jan 31.
22. van Doorn L, Crombag MBS, Rier HN, van Vugt JLA, van Kesteren C, Bins S, et al. The Influence of Body Composition on the Systemic Exposure of Paclitaxel in Esophageal Cancer Patients. *Pharmaceuticals (Basel)* 2021;14(1):47. doi: 10.3390/ph14010047.
23. Derstine BA, Holcombe SA, Ross BE, Wang NC, Su GL, Wang SC. Skeletal muscle cutoff values for sarcopenia diagnosis using T10 to L5 measurements in a healthy US population. *Sci Rep* 2018;8(1):11369. doi: 10.1038/s41598-018-29825-5.
24. Krishnamurthy V, Zhang P, Ethiraj S, Enchakalody B, Waljee AK, Wang L, et al. Use of analytic morphomics of liver, spleen, and body composition to identify patients at risk for cirrhosis. *Clin Gastroenterol Hepatol* 2015;13(2):360-8.e5. doi: 10.1016/j.cgh.2014.07.042. Epub Jul 30.

25. Kraff S, Lindauer A, Joerger M, Salamone SJ, Jaehde U. Excel-Based Tool for Pharmacokinetically Guided Dose Adjustment of Paclitaxel. *Ther Drug Monit* 2015;37(6):725-32 doi 10.1097/ftd.0000000000000206.
26. Joerger M, Huitema ADR, van den Bongard DHJG, Schellens JHM, Beijnen JH. Quantitative Effect of Gender, Age, Liver Function, and Body Size on the Population Pharmacokinetics of Paclitaxel in Patients with Solid Tumors. *Clinical Cancer Research* 2006;12(7):2150-7 doi 10.1158/1078-0432.CCR-05-2069.
27. Burnham KP, Anderson DR. Multimodel Inference: Understanding AIC and BIC in Model Selection. *Sociological Methods & Research* 2004;33(2):261-304 doi 10.1177/0049124104268644.
28. Prado CM, Baracos VE, McCargar LJ, Mourtzakis M, Mulder KE, Reiman T, et al. Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. *Clin Cancer Res* 2007;13(11):3264-8. doi: 10.1158/078-0432.CCR-06-3067.
29. Cespedes Feliciano EM, Lee VS, Prado CM, Meyerhardt JA, Alexeeff S, Kroenke CH, et al. Muscle mass at the time of diagnosis of nonmetastatic colon cancer and early discontinuation of chemotherapy, delays, and dose reductions on adjuvant FOLFOX: The C-SCANS study. *Cancer* 2017;123(24):4868-77. doi: 10.1002/cncr.30950. Epub 2017 Sep 7.
30. Cespedes Feliciano EM, Chen WY, Lee V, Albers KB, Prado CM, Alexeeff S, et al. Body Composition, Adherence to Anthracycline and Taxane-Based Chemotherapy, and Survival After Nonmetastatic Breast Cancer. *JAMA Oncol* 2020;6(2):264-70. doi: 10.1001/jamaoncol.2019.4668.
31. Chemama S, Bayar MA, Lanoy E, Ammari S, Stoclin A, Goéré D, et al. Sarcopenia is Associated with Chemotherapy Toxicity in Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis from Colorectal Cancer. *Ann Surg Oncol* 2016;23(12):3891-8. doi: 10.1245/s10434-016-5360-7. Epub 2016 Jun 28.
32. Trobec K, Kerec Kos M, von Haehling S, Springer J, Anker SD, Lainscak M. Pharmacokinetics of drugs in cachectic patients: a systematic review. *PLoS One* 2013;8(11):e79603. doi: 10.1371/journal.pone.0079603. eCollection 2013.
33. Kumar GN, Walle UK, Bhalla KN, Walle T. Binding of taxol to human plasma, albumin and alpha 1-acid glycoprotein. *Research communications in chemical pathology and pharmacology* 1993;80(3):337-44.
34. Desmedt C, Fornili M, Clatot F, Demicheli R, De Bortoli D, Di Leo A, et al. Differential Benefit of Adjuvant Docetaxel-Based Chemotherapy in Patients With Early Breast Cancer According to Baseline Body Mass Index. *J Clin Oncol* 2020;38(25):2883-91. doi: 10.1200/JCO.19.01771. Epub 2020 Jul 2.
35. Beumer JH, Chu E, Allegra C, Tanigawara Y, Milano G, Diasio R, et al. Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy. *Clin Pharmacol Ther* 2019;105(3):598-613. doi: 10.1002/cpt.124. Epub 2018 Sep 11.
36. Salgado TM, Quinn CS, Krumbach EK, Wenceslao I, Gonzalez M, Reed HL, et al. Reporting of paclitaxel-induced peripheral neuropathy symptoms to clinicians among women with breast

- cancer: a qualitative study. *Support Care Cancer* 2020;28(9):4163-72. doi: 10.1007/s00520-019-5254-6. Epub 2020 Jan 2.
37. Bandos H, Melnikow J, Rivera DR, Swain SM, Sturtz K, Fehrenbacher L, et al. Long-term Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant Chemotherapy: NRG Oncology/NSABP B-30. *J Natl Cancer Inst* 2018;110(2) doi 10.1093/jnci/djx162.
38. Shimozuma K, Ohashi Y, Takeuchi A, Aranishi T, Morita S, Kuroi K, et al. Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial. *Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer* 2012;20(12):3355-64 doi 10.1007/s00520-012-1492-x; 10.1007/s00520-012-1492-x.
39. Hertz DL, Childs DS, Park SB, Faithfull S, Ke Y, Ali NT, et al. Patient-centric decision framework for treatment alterations in patients with Chemotherapy-induced Peripheral Neuropathy (CIPN). *Cancer Treat Rev* 2021;99:102241.(doi):10.1016/j.ctrv.2021.102241.
40. Loibl S, Skacel T, Nekljudova V, Luck HJ, Schwenkglenks M, Brodowicz T, et al. Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysis. *BMC Cancer* 2011;11:131 doi 10.1186/1471-2407-11-131.
41. Derstine BA, Holcombe SA, Goulson RL, Ross BE, Wang NC, Sullivan JA, et al. Quantifying Sarcopenia Reference Values Using Lumbar and Thoracic Muscle Areas in a Healthy Population. *J Nutr Health Aging* 2017;21(10):180-5. doi: 10.1007/s12603-017-0983-3.

Table 1: Patient, Treatment, and Morphomics Data for Patients Included in the Analysis (n=39)

| | | N or Mean | % or Range |
|---|--|------------------|-------------------|
| Age | Years | 50 | 28 to 71 |
| Self-Reported Race | White | 35 | 90% |
| | African American | 2 | 5% |
| | Asian | 2 | 5% |
| Weight | Kg | 71 | 48 to 134 |
| Height | meters | 1.63 | 1.55 to 1.78 |
| Albumin | g/dL | 4.0 | 2.0 to 4.5 |
| Infusion Duration | 90 minutes | 38 | 97% |
| | 180 minutes | 1 | 3% |
| Vertebral Level with Available Morphomics Data | Thoracic 10 (T10) | 37 | 95% |
| | Thoracic 11 (T11) | 39 | 100% |
| | Thoracic 12 (T12) | 36 | 92% |
| | Lumbar 1 (L1) | 33 | 85% |
| | Lumbar 2 (L2) | 32 | 82% |
| | Lumbar 3 (L3) | 32 | 82% |
| | Lumbar 4 (L4) | 32 | 82% |
| | Skeletal Muscle Area (mm ²) | 8382 | 4825 to 11732 |
| Morphomics Measures at T11 | Visceral Fat Area (mm ²) | 5979 | 613 to 17341 |
| | Subcutaneous Fat Area (mm ²) | 13576 | 2325 to 35036 |
| | Height of Slab at Vertebra (mm) | 28.3 | 25.0 to 32.7 |
| | Skeletal Muscle Density (HU) | 41.4 | 28.4 to 53.7 |
| | Visceral Fat Density (HU) | -95.9 | -107 to -84.7 |
| | Subcutaneous Fat Density (HU) | -103 | -112 to -89.3 |

HU: Hounsfield Units

Table 2: Comparison of the population pharmacokinetic parameters of the base model, body surface area (BSA) model, and morphomic model (selected as the final model)

| | Base Model AIC=849.02 | | | BSA Model AIC= 834.92 | | | Morphomic Model AIC=828.52 | | |
|---|--------------------------|-------|------------|--------------------------|-------|------------|-------------------------------|-------|------------|
| | VALUE | S.E. | R.S.E. (%) | VALUE | S.E. | R.S.E. (%) | VALUE | S.E. | R.S.E. (%) |
| Fixed Effects | | | | | | | | | |
| Cl_pop | 29.77 | 6.7 | 22.5 | 20.16 | 1.91 | 9.49 | 18.43 | 0.52 | 2.85 |
| V1_pop | 28.55 | 8.33 | 29.2 | 41.52 | 2.88 | 6.93 | 43.51 | 2.59 | 5.95 |
| θ_1 | N/A | N/A | N/A | 1.64 | 0.47 | 28.6 | N/A | N/A | N/A |
| θ_2 | N/A | N/A | N/A | N/A | N/A | N/A | 1.09 | 0.3 | 27.4 |
| Q_pop | 0.313 | 0.106 | 33.7 | 3.66 | 0.44 | 12 | 3.15 | 0.26 | 8.19 |
| V2_pop | 0.336 | 0.138 | 41.1 | 115.2 | 13.33 | 11.6 | 109.62 | 12.51 | 11.4 |
| θ_3 | N/A | N/A | N/A | 3.12 | 0.56 | 17.9 | N/A | N/A | N/A |
| θ_4 | N/A | N/A | N/A | N/A | N/A | N/A | 2.22 | 0.25 | 11.2 |
| Standard Deviation of the Random Effects | | | | | | | | | |
| omega_Cl | 0.14 | 0.044 | 30.7 | 0.075 | 0.094 | 125 | 0.046 | 0.032 | 71.1 |
| omega_V1 | 0.45 | 0.52 | 115 | 0.21 | 0.075 | 35.7 | 0.19 | 0.067 | 36 |
| omega_Q | 0.093 | 0.25 | 269 | 0.076 | 0.029 | 38.2 | 0.097 | 0.045 | 46.1 |
| omega_V2 | 0.23 | 0.34 | 145 | 0.12 | 0.091 | 77.3 | 0.098 | 0.12 | 122 |
| Error Model Parameters | | | | | | | | | |
| b | 0.19 | 0.11 | 56 | 0.21 | 0.065 | 31.4 | 0.21 | 0.031 | 15 |

S.E.: Standard Error, R.S.E: Relative Standard Error, AIC: Akaike Information Criterion


$$V1 = V1_{pop} \times (BSA/1.87)^{\theta_1}$$

$$V1 = V1_{pop} \times (SMA/8000)^{\theta_2}$$


$$V2 = V2_{pop} \times (BSA/1.87)^{\theta_3}$$

$$V2 = V2_{pop} \times (SMA/8000)^{\theta_4}$$

b = proportional error term



BCP_15244_CmaxPTA_hiRes.tif



BCP_15244_Hertz_PacMorphomics_Fig1_2021_5_3.jpg